Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Core Viewpoint - Karyopharm Therapeutics Inc. will report its fourth quarter and full year 2025 financial results on February 12, 2026, and will host a conference call to discuss these results and other updates [1]. Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly through oral compounds that address nuclear export dysregulation, a key mechanism in oncogenesis [3]. - The company's lead compound, XPOVIO (selinexor), is a first-in-class oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in over 50 territories, including the EU, UK (as NEXPOVIO), and China [3]. - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3].